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ANKHD1 is required for SMYD3 to promote
tumor metastasis in hepatocellular
carcinoma
Zhenyu Zhou1,2†, Hai Jiang1,3†, Kangsheng Tu4†, Wei Yu1,2, Jianlong Zhang1,2, Zhigang Hu5, Heyun Zhang1,2,
Dake Hao6, Pinbo Huang1,2, Jie Wang1,2, Aijun Wang6*, Zhiyu Xiao1,2* and Chuanchao He1,2*
Absract
Background: Tumor metastasis is the major reason for poor prognosis of hepatocellular carcinoma (HCC) patients
after hepatic resection. SMYD3 has been demonstrated to promote liver tumor metastasis in mice. However, the
detailed molecular mechanism is still largely unknown.
Methods: The effect of SMYD3 on invasiveness and metastasis of HCC was analyzed by immunohistochemistry,
migration assay, invasion assay, wound healing assay and in vivo lung metastasis assay. Mass spectrometry analysis
was conducted using proteins pulled down by H3K4me3 antibody in SMYD3-overexpressing cells. Luciferase
reporter, chromatin immunoprecipitation, Electrophoretic mobility shift assay were used to measure the regulation
of SLUG transcription by SMYD3-ANKHD1. In addition, the role of SMYD3-ANKHD1 in determining clinical outcomes
for HCC patients was investigated by immunohistochemistry in 243 HCC tissues.
Results: SMYD3 was an independent prognostic factor of HCC and promoted migration and invasion of human
HCC cells. ANKHD1 was identified by mass spectrometry as a co-regulator with SMYD3. ANKHD1 interacted with
H3K4me3 when cells were overexpressing SMYD3. The pro-migratory and pro-invasive effects of SMYD3 were
attenuated when ANKHD1 was knocked down by siRNA. Furthermore, we found that SMYD3 bound and activated
the SLUG gene promoter in a manner associated with elevating H3K4me3, H3K9Ac and H3K14Ac. Knockdown of
ANKHD1 could attenuate the SMYD3-dependent activation of Slug expression. We further detected the expression
of SMYD3 and ANKHD1 in 243 HCC patients and found that patients with positive coexpression of SMYD3 and
ANKHD1 (SMYD3+ANKHD1+) had the shortest overall and recurrence-free survival.
Conclusion: Our findings provide a novel molecular mechanism for the SMYD3-regulated HCC migration and
metastasis, and indicates that SMYD3-ANKHD1 may be a potential target for treating HCC.
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Background
Although many therapeutic methods have been applied
in the treatment of hepatocellular carcinoma (HCC),
HCC is still ranked the second leading cause of
cancer-related death globally [1]. High morbidity of me-
tastasis is the major reason for poor prognosis of HCC
patients, even of those with curative surgical treatment
[2]. Thus, understanding the mechanisms of HCC me-
tastasis will provide new opportunities for preventing
HCC patients from poor treatment outcomes.
SET and MYND domain-containing protein 3 (SMYD3)
is a lysine methyltransferase that was first identified and
characterized in 2004 [3]. Although subsequent studies
have identified SMYD3 as a H4K5 methyltransferase,
H2A.Z.1 K101 dimethyltransferase, and protein lysine
methyltransferase [4–6], SMYD3 plays the most critical
role through its H3K4 methyltransferase activity [7, 8].
Until now, many oncogenes have been demonstrated to
be regulated on transcriptional level by SMYD3 through
trimethyl-H3K4 (H3K4me3) modification, which high-
lights the role of SMYD3 as an essential epigenetic regula-
tor in cancer cells [9]. Furthermore, accumulated evidence
suggests that SMYD3 is now considered to play a funda-
mental role in human tumorigenesis [8, 10–12]. These in-
formation suggest that SMYD3 may also act as an
epigenetic regulator in promoting HCC development and
progression. Actually, recent studies have indicated that
SMYD3 is associated with liver carcinogenesis of mice
and poor prognosis of HCC patients [7, 13, 14]. However,
the detailed molecular mechanism of how SMYD3 pro-
motes HCC metastasis needs further investigation.
Post-translational modifications (PTM) of histones,
like H3K4me3, are recognized by so-called “reader” pro-
teins via specialized binding modules [15]. In most cases,
the binding of a reader to its cognate histone PTM can
stimulate a series of molecular processes such as protein
recruitment and histone modifications, and finally affect
gene expression [16]. ANKHD1 (Ankyrin Repeat and
KH Domain Containing 1), also known as MASK1, con-
tains two domains: ankyrin repeats domain and KH do-
main [17], among which the ankyrin repeats domain has
been demonstrated to be able to bind H3K9me2,
H3K9me1 [18]. In recent years, ANKHD1 has been
shown as a potential biomarker in various cancers [19–
21]. However, whether ANKHD1 could bind a specific
histone mark and serve as an tumor promoter in HCC is
not yet known.
In this study, by conducting mass spectrometry ana-
lysis, we identified ANKHD1 as a co-regulator with
SMYD3. We provided evidence that SMYD3 transacti-
vates its target genes and promotes HCC cells migration
and invasion through ANKHD1. Moreover, we found
that SMYD3-ANKHD1 correlates with the prognosis of
HCC patients.
Methods
Patients and follow-up
A total of 243 patients with HCC who underwent cura-
tive resection between 2010 and 2013 at the Sun Yat-Sen
Memorial Hospital were enrolled in this study. This
study was conducted in accordance with the Declaration
of Helsinki. The study protocol was approved by the re-
search ethics committee of Sun Yat-Sen Memorial Hos-
pital, and written informed consent was obtained from
each patient. The diagnosis of HCC was based on path-
ology and dynamic contrast-enhanced imaging (com-
puted tomography scan or magnetic resonance imaging).
Briefly, the inclusion criteria were: (1) distinctive patho-
logic diagnosis of HCC, (2) no anti-cancer treatment be-
fore hepatic resection, (3) suitable formalin-fixed,
paraffin-embedded tissues, and (4) complete clinicopath-
ologic data. The detailed clinical characteristics of the
243 patients are summarized in Supplementary Table S1.
The TNM classification for HCC was based on The
American Joint Committee on Cancer/TNM Staging for
Liver Tumors (7th edition, 2010). The median follow-up
of this cohort was 39.34 months.
In addition, a total of 25 pairs of primary HCC tissues
and major portal vein tumor thrombi (mPVTTs) were
collected after surgical resection for further immunohis-
tochemistry. The study protocol was approved by the
research ethics committee of Sun Yat-Sen University.
Written informed consents were obtained from these
patients.
In vivo lung metastasis assay
All animal experiments were performed in accordance
with current Chinese regulations and standards regard-
ing the use of laboratory animals, and approved by the
animal ethics committee of Sun Yat-sen University. In
brief, cells were injected into ten 4-week-old BALB/c
nude mice intravenously (1 × 106 cells/ mouse).
OMe-modified control and ANKHD1 siRNA were intra-
venously injected into the mice from tail vein (5 μg/g/
mouse) twice a week at the second week after tumor
cells injection. After 4 weeks, the mice were euthanized
and sacrificed. Lungs of the mice were removed and
fixed in Bouin’s solution for 24 h. The number of lung
surface metastatic foci was then counted. Lungs were ex-
cised and embedded in paraffin for further study.
Subcellular fractionation
Cytoplasmic and nuclear fractions were prepared from
5 × 107 cells by using Minute™ Cytoplasmic & Nuclear
Extraction Kits (Invent Biotechnologies, USA). Briefly,
cells were washed with ice-cold PBS and lysed for 30
min on ice with cytoplasmic lysis buffer. The lysates
were centrifuged at 14000 rpm for 5 min at 4 °C, and the
supernatants (cytoplasmic fractionation) were collected
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in a fresh tube kept on ice. The pellet was resuspended
with nuclear lysis buffer. The homogenate was incubated
on ice for 30 min on ice and centrifuged at 14000 rpm
for 5min at 4 °C. Supernatant was collected as the nu-
clear fraction. The cytoplasmic and nuclear fractions
were then analyzed using western blot.
Co-immunopreciptation (co-IP)
Total protein lysate was obtained in immunoprecipita-
tion buffer. 500 μg of total protein was mixed with 1 μg
the primary antibody, or IgG, and the mixture were
shaken on a rotating shaker at 4 °C for 1 h. Beads (Santa,
USA) were added to the mixture and shaken at 4 °C
overnight. Then the beads were collected by centrifuga-
tion at 2500 rpm for 5min at 4 °C, and then washed 4
times by immunoprecipitation buffer. 5× sample loading
buffer was added to the beads before boiling for 5 min.
The supernatant was collected and detected using west-
ern blot.
Luciferase reporter assay
The Slug luciferase reporter plasmid (pGL4.18-Slug-WT)
was generated by inserting a DNA fragment which con-
tained the snai2 5′-flanking region from − 359 to + 109
into pGL4.18 vector (Promega, USA). Mutation reporter
plasmids (pGL4.18-Slug-M1 and pGL4.18-Slug-M2) were
made by replacing the two SMYD3 binding sequences
(5’-CCCTCC-3′ to 5’-CAAGAC-3′) in pGL4.18-Slug-WT
using the MutanBEST Kit (TaKaRa, Japan) according to
the manufacturer’s instructions. Primer sequences of plas-
mid construction are listed in Additional file 1: Table S7.
Cells were transfected with pGL4.18-Slug-WT,
pGL4.18-Slug-M1 or pGL4.18-Slug-M2 combined with
pCDNA3.1-SMYD3, siANKHD1 or negative control using
ViaFect™ Transfection Reagent (Promega, USA). For each
set of transfections, pGL4.74 (Promega, USA) was always
included to control transfection efficiency. At 48 h after
transfection, luciferase activity was measured using a dual
luciferase reporter assay system (Promega, USA) accord-
ing to the manufacturer’s instructions.
Electrophoretic mobility shift assay (EMSA)
Biotin end-labeled probe was prepared by Sangon Biotech
(China). EMSA was performed using the LightShift®
Chemiluminescent EMSA Kit (Pierce, USA) according to
the manufacturer’s instructions. DNA binding reactions
were performed in 20 μL system containing biotin-labeled
oligonucleotides and nuclear extracts. Additional
unlabeled oligonucleotides were added for competition.
Reaction products were then separated by electrophoresis.
Thereafter, the protein-DNA complexes were transferred
onto a positively charged nylon membrane (Millipore,
USA) and detected by chemiluminescence.
Chromatin immunoprecipitation assay (ChIP)
ChIP assays were performed using EZ-CHIP Kit according
to the manufacturer’s instruction (Millipore, USA). Briefly,
cells were cross-linked using 1% formaldehyde. After wash-
ing with PBS, the cells were resuspended in 1mL of SDS
lysis buffer containing protease inhibitor cocktail. DNA was
sheared to small fragments (200–300 bp) by sonication.
The sheared chromatin was immunoprecipitated with dif-
ferent antibodies (Additional file 2) overnight at 4 °C. DNA
from immunoprecipitation and the input samples was
analyzed using SYBR Green qPCR Master Mix (Biotool,
USA). Primers were shown in Additional file 1: Table S7.
Statistical analysis
Statistical analysis was performed with SPSS software
(version 17.0). Cumulative survival and recurrence rates
were calculated by the Kaplan-Meier analysis and the
log-rank test. Based on the variables selected on univari-
ate analysis, the multivariate Cox proportional hazards
model was used to determine the independent prognos-
tic factors of HCC. Quantitative data and categorical
data were analyzed by the Student’s t test and Fisher’s
exact test, respectively. P < 0.05 was considered statisti-
cally significant.
Results
SMYD3 promotes HCC cells migration and invasion
We first assessed SMYD3 expression in a tissue microarray
of 243 HCC samples. SMYD3 expression was found in 188
of 243 (77.4%) primary HCC tissues (Fig. 1a). SMYD3 posi-
tive expression in HCC was significantly associated with
HBV infection, microvascular invasion, poor tumor differ-
entiation, and high TNM stage (Additional file 1: Table S1).
Furthermore, HCC patients with positive SMYD3 expres-
sion had shorter overall and recurrence-free survival com-
pared with those with negative SMYD3 expression (Fig.
1b). Cox’s multivariate proportional hazards model indi-
cated that the expression of SMYD3 was an independent
predictor of survival (P = 0.012) and recurrence (P = 0.028)
in HCC patients after curative resection (Additional file 1:
Table S2).
To further explore the oncogenic mechanism of
SMYD3 in HCC, we chose Bel-7402 and huh7 to estab-
lish cell lines that stably overexpressed SMYD3 (Fig. 1c;
Additional file 3: Figure. S1A). Besides, MHCC97H was
chosen to establish SMYD3 stable knockdown cell line
(Fig. 1c; Additional file 3: Figure S1A). Both upregulation
and knockdown of SMYD3 expression were confirmed
by real-time PCR and western blot (Fig. 1d and e; Add-
itional file 3:Figure S1B- S1D). We found that upregula-
tion of SMYD3 significantly enhanced the migration and
invasion capacities of huh7 and Bel-7402 cells (Fig. 1f
and g; Additional file 3: Figure S1E and S1F). In con-
trast, knockdown of SMYD3 markedly reduced cell
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migration and invasion in MHCC97H cells (Fig. 1h
and i). To evaluate the in vivo effects of SMYD3 on
HCC metastasis, Bel-7402-SMYD3 cells were injected
into the tail veins of nude mice. The incidence of
lung metastasis in the SMYD3-overexpressing group
was significantly higher than that in the control group
(Fig. 1j). These results suggest that SMYD3 is an im-
portant factor in during HCC progression.
Identification of ANKHD1 as a co-regulator with SMYD3
SMYD3 plays the most critical role through its H3K4
methyltransferase activity [8]. To investigate whether
Fig. 1 SMYD3 is associated with poor prognosis of HCC and promotes HCC cells migration and invasion. a IHC analysis of SMYD3 expression in
HCC tissues. b Kaplan-Meier analysis of the overall survival or recurrence-free survival in HCC patients according to SMYD3 expression. c Western
blot analysis of SMYD3 expression in different HCC cell lines. d) and e Real-time PCR and western blot confirmed the efficiencies of SMYD3 stable
overexpression in huh7 cells and stable knockdown in MHCC97H cells, respectively. f and g Wound healing assay, migration assay and invasion
assay were performed in SMYD3-overexpressing cells. h and i Wound healing assay, migration assay and invasion assay were performed in SMYD3
knockdown cells. j In vivo lung metastasis assay was used to evaluate the in vivo effects of SMYD3 on tumor metastasis by tail vein injections of cells;
representative images of H&E-stained sections were derived from lung metastatic nodules of both groups; Number of metastatic lung foci observed at
the surface of the lungs of mice was counted in each group (n = 6). Data are presented as mean ± SD for three independent experiments. *P < 0.05
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there exist proteins that bind to H3K4me3 under
SMYD3 overexpression and influence target genes ex-
pression, we applied mass spectrometry analysis using
proteins pulled down by H3K4me3 antibody in
SMYD3-overexpressing cells. Interestingly, we found
ANKHD1 could specifically bind to H3K4me3 when
cells were overexpressing SMYD3 (Additional file 1:
Table S3). Our further validation by Co-IP showed that
SMYD3 overexpression lead to the interaction between
ANKHD1 and H3K4me3, whereas knockdown of
SMYD3 inhibited these interactions (Fig. 2a; Additional
file 3: Figure S2A, S2C and S2D). Moreover, subcellular
fractionation and immunofluorescent staining showed
that ANKHD1 and H3K4me3 co-localized in the nuclei
when SMYD3 was overexpressed (Fig. 2b and c; Add-
itional file 3: Figure S2B). In addition, we also detected
the co-localization of SMYD3 and ANKHD1. Results
showed that SMYD3 was colocalized with ANKHD1 in
both cytoplasm and nucleus, especially in cytoplasm
(Additional file 3: Figure S2E). These data suggest that
ANKHD1 may be involved in regulating the expression
of SMYD3-targeted genes.
ANKHD1 expression correlates with metastatic potential
and patients survival of HCC
ANKHD1 is overexpressed in multiple malignant tu-
mors, such as acute leukemias [19], renal cancer cell
[20], and breast cancer [21]. However, little is known in
HCC. Our IHC results in tissue microarray showed that
150 of 243 (61.7%) primary HCC tissues have positive
ANKHD1 expression (Fig. 2c). Positive expression of
ANKHD1 was significantly associated with large tumor
size, microvascular invasion, multiple nodules, poor
tumor differentiation, and high TNM stage (Additional
Fig. 2 ANKHD1 is a co-regulator with SMYD3 and is associated with poor prognosis of HCC. a Lysates of huh7-SMYD3 and huh7-control cells
were immunoprecipitated for endogenous H3K4me3 or ANKHD1 and immunoblotted for ANKHD1 or H3K4me3, respectively. b Subcellular
fractions were isolated to analyze the coexpression of SMYD3, ANKHD1 and H3K4me3 in cytoplasm and nucleus using western blot. c Confocal
analysis of HCCLM3 and huh7 cells transfected with SMYD3 displaying ANKHD1 (green), H3K4me3 (red) and DAPI (blue) staining; MERGE shows
the overlapped images. d IHC analysis of SMYD3 expression in HCC tissues. e Kaplan-Meier analysis of the overall survival or recurrence-free
survival in HCC patients according to ANKHD1 expression
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file 1: Table S1). HCC patients with positive ANKHD1
expression were associated with significantly shorter
overall and recurrence-free survival (Fig. 2d). Moreover,
the expression of ANKHD1 in HCC cells was higher
as the invasion potential of HCC cells increased.
(Additional file 3: Figure S2F). ANKHD1 overexpres-
sion significantly enhanced the migration and invasion
capacities of HCC cell line, Bel-7402 (Additional file
3: Figure S2G-S2I). These data suggest that, similar to
SMYD3, ANKHD1 is also associated with the aggres-
siveness of HCC progression.
ANKHD1 mediates the pro-migratory and pro-invasive
effects of SMYD3
To investigate whether ANKHD1 could regulate onco-
genic mechanism of SMYD3 in HCC, huh7-SMYD3 cells
were transfected with siRNA to knock down ANKHD1
expression. ANKHD1 knockdown significantly reduced
SMYD3-enhanced cell migration and invasion (Fig. 3a
and b). Moreover, inhibition of ANKHD1 expression in
SMYD3-overexpressing cells significantly attenuated the
incidence of lung metastasis induced by SMYD3 in vivo
(Fig. 3c). Interestingly, overexpressing ANKHD1 in the
condition of SMYD3 knockdown did not influence the
migration and nvasion capacities of MHCC97H (Add-
itional file 3: Figure S3A and S3B). These data suggests
that SMYD3 promotes HCC invasion and metastasis
through ANKHD1.
Identification Slug as a target of SMYD3-ANKHD1 in HCC
Given the findings above, we sought to determine
whether SMYD3-ANKHD1 regulated SMYD3 target
genes in HCC cells. We found that ANKHD1 could
mediate the upregulation of SMYD3 target genes
(Fig. 4a). In addition, because the results above
showed that SMYD3-ANKHD1 promoted HCC cells
migration and invasion, we also detected the expres-
sion of five EMT-inducing transcription factors. Our
results showed that the mRNA expression of Slug
was regulated by SMYD3-ANKHD1, in contrast, no
differences were found in the other four transcription
factors (Fig. 4a). Results from western blot in SMYD3
stable overexpressing or knockdown cells and cells
with SMYD3 inhibition, and IHC in 25 pairs of pri-
mary HCC tissues, mPVTTs, as well as microvascular
invasion (MVIs) further supported the regulation of
Slug by SMYD3 (Additional file 3: Figure S4A-S4C,
Figure S5A; Additional file 1: Table S4). Furthermore,
knockdown of ANKHD1 significantly reduced
SMYD3-dependent expression of Slug, and attenuated
the loss of E-cadherin expression on protein levels
(Fig. 4b). We therefore selected Slug for the following
investigation.
SMYD3 is known to bind to a putative motif CCCT
CC in its target genes promoters [22]. Interestingly, we
identified two putative SMYD3 binding elements within
the SLUG gene promoter region (Fig. 4c). To determine
whether SMYD3 regulated Slug transcription and define
which putative binding site was responsible for the regu-
lation, luciferase reporter assay was performed. Results
showed that SMYD3 enhanced SLUG gene promoter ac-
tivity, but the enhancement was abolished when the
binding site 1 was mutated (Fig. 4d), indicating that
SMYD3 activates Slug transcription through binding site
1. Then, we performed EMSA and ChIP assay to deter-
mine whether SMYD3 physically bound to the SLUG
gene promoter. EMSA showed that oligonucleotides
probe corresponding to binding site 1 of the SLUG gene
promoter strongly combined with SMYD3, and these
SMYD3-labeled probe complexes were abrogated by the
unlabeled oligonucleotides (Fig. 4e). We next performed
ChIP assay to determine whether the interaction exists
under physiological conditions. As shown in Fig. 4F, in-
creasing binding of SMYD3 to binding site 1 of the
SLUG gene promoter was found in cells overexpressing
SMYD3. Furthermore, SMYD3 upregulation increased
H3K4 trimethylation, H3K9 and H3K14 acetylation in
the same region, while SMYD3 inhibition by BCI-121
decreased H3K4 trimethylation, indicating that SMYD3
is required for increasing trimethylation of H3K4 and
acetylation of H3K9/14 in the SLUG gene promoter (Fig.
4g and h; Additional file 3: Figure S5B and S5C). Taken
together, these results suggest that SMYD3 is an epigen-
etic regulator of Slug expression in HCC, which results
in H3K4 trimethylation and subsequent H3K9, K14
acetylation in the SLUG gene promoter.
SMYD3 transactivates Slug expression through ANKHD1
As our above results showed that ANKHD1 bind to
H3K4me3 under SMYD3 overexpression, we next inves-
tigated whether ANKHD1 mediates the transactivation
of SLUG gene by SMYD3. We found that SMYD3 over-
expression recruited significantly more ANKHD1 to
binding site 1 of the SLUG gene promoter than binding
site 2, while SMYD3 inhibition by BCI-121 prevented
this recruitment (Fig. 5a and b). However, knockdown of
ANKHD1 did not affect the recruitment of SMYD3 or
the trimethylation of H3K4 on the SLUG gene promoter
(Fig. 5c and d). Interestingly, the attenuated effect of
ANKHD1 knockdown on SLUG gene promoter activity
in SMYD3-overexpressing cells was significantly weak-
ened when the binding site 1 was mutated (Fig. 5e). To-
gether, these data suggest that SMYD3-dependent
increase of H3K4 trimethylation can recruit ANKHD1
to SLUG gene promoter, which mediates the
SMYD3-induced transactivation of SLUG gene
promoter.
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SMYD3-ANKHD1 correlate with HCC patient outcomes
To explore the role of SMYD3-ANKHD1 in determining
clinical outcomes for HCC patients, we assessed the cor-
relation between SMYD3-ANKHD1 and the prognosis
of 243 HCC patients. Although no significant relation-
ship was found between the expression level of SMYD3
and ANKHD1 in the 243 HCC tissues (Fig. 6a;
Additional file 3: Figure S6A-S6C; Additional file 1:
Table S5), Kaplan-Meier analysis revealed that patients
with positive coexpression of SMYD3 and ANKHD1
(SMYD3+ANKHD1+) had the shortest overall and
recurrence-free survival (Fig. 6b). Noteworthily, there
were no significant differences in recurrence-free sur-
vival rates among patients with SMYD3+ANKHD1−,
SMYD3−ANKHD1+ or SMYD3−ANKHD1− (Fig. 6b;
Additional file 3: Figure S6D-S6F). Furthermore, we also
assessed the correlation between Slug and SMYD3/
ANKHD1 expression in 243 HCC clinical samples. We
Fig. 3 ANKHD1 mediates the pro-migratory and pro-invasive effects of SMYD3. a Migration and invasion assay in stable huh7-SMYD3 cells with
ANKHD1 knockdown or not. b Wound healing assay of huh7-SMYD3 cells with ANKHD1 knockdown or not. c In vivo lung metastasis assay was
performed using Bel-7402 control, Bel-7402-SMYD3, and Bel-7402-SMYD3 combined with ANKHD1 siRNA or control siRNA injection; representative
images of H&E-stained sections were derived from lung metastatic nodules of the four experimental groups; Number of metastatic lung foci
observed at the surface of the lungs of mice was counted in each group (n = 6 for each group). Data are presented as mean ± SD for three
independent experiments. *P < 0.05
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found that Slug expression was correlated with
ANKHD1 expression in SMYD3 positive HCC patients,
but not in SMYD3 negative HCC patients, suggesting
both SMYD3 and ANKHD1 are necessary for Slug ex-
pression in HCC (Additional file 3: Figure S7; Additional
file 1: Table S6). These data provide clinical evidence
Fig. 4 Identification Slug as a target of SMYD3-ANKHD1 in HCC. a Real-time PCR was performed to detect the mRNA expression of SMYD3-
dependent target genes and EMT- inducing transcription factors in huh7 cells stably overexpressing SMYD3 with or without ANKHD1 knockdown.
b Western blot detection of the expression of E-cadherin and Slug in huh7 cells stably overexpressing SMYD3 with or without ANKHD1 knockdown. c
Two putative SMYD3 binding sites in human SLUG gene promoter region. d Luciferase reporter assay of huh7 cells cotransfected with the indicated
luciferase reporter (wide type SLUG gene promoter-luciferase construct or its SMYD3 binding site mutants) and the empty vector or SMYD3 expression
vector. e Nuclear extracts prepared from cells treated with pCDNA3.1-SMYD3 or pCDNA3.1-control were incubated with the biotin-labeled
oligonucleotides probe corresponding to binding site 1 in the SLUG gene promoter to perform EMSA. Different fold excess of unlabeled
oligonucleotides probe for binding site 1 were used to compete with the interaction between the labeled probe and SMYD3. f-h ChIP
assays were performed in huh7-control and huh7-SMYD3 stable cell lines using antibodies against SMYD3, H3K4me3, and H3K9, K14Ac;
immunoprecipitated DNA was measured by real-time PCR using primers for amplifying the SMYD3-binding regions in the SLUG gene
promoter. Data are shown as mean ± SD of three separate experiments. *P < 0.05
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that ANKHD1 acts as a co-regulator with SMYD3 in
promoting HCC progression.
Discussion
Many histone modifications have been implicated in in-
fluencing gene expression. For instance, the methylation
of H3K4, H3K36, H3K79 and the acetylation of H3K9,
H3K14 are closely correlated with transcriptional activa-
tion; whereas the methylation of H3K9, H3K27 and
H4K20 is associated with gene repression [23].
Deregulation of these histone modifications will lead to
changes in the expression of several oncogenes that ul-
timately result in cancer development and progression
[24]. Thus, it is critical to understand the underlying epi-
genetic molecular mechanisms in HCC. SMYD3, as a
histone H3K4 methyltransferase, has received consider-
able attention in the last few years due to its critical
roles in multiple malignant processes, especially in
tumor invasion and metastasis [8, 22]. Recent study has
shown that SMYD3 was associated with EMT in HCC
Fig. 5 SMYD3 transactivates Slug expression through ANKHD1. a ChIP assays were performed in huh7-control and huh7-SMYD3 stable cell lines
using antibodies against ANKHD1; immunoprecipitated DNA was measured by real-time PCR using primers for amplifying the SMYD3-binding
regions in the SLUG gene promoter. b ChIP assays were performed in MHCC97H with and without SMYD3 inhibitor (BCI-121) treatment using
antibodies against ANKHD1; immunoprecipitated DNA was measured by real-time PCR using primers for amplifying the SMYD3-binding regions
in the SLUG gene promoter. c and d ChIP assays were performed in huh7-control and huh7-SMYD3 stable cell lines with or without ANKHD1
knockdown using antibodies against SMYD3 and H3K4me3; immunoprecipitated DNA was measured by real-time PCR using primers for
amplifying the SMYD3-binding regions in the SLUG gene promoter. (E) Luciferase reporter assay of huh7 cells cotransfected with the indicated
luciferase reporter (wide type SLUG gene promoter-luciferase construct or its SMYD3 binding site mutants), the empty vector or SMYD3
expression vector, and control siRNA or ANKHD1 siRNA. Data are shown as mean ± SD of three separate experiments. *P < 0.05
Fig. 6 SMYD3-ANKHD1 correlate with HCC patient outcomes. a HCC tissue with concurrent SMYD3 and ANKDH1 positive expression. b Kaplan-
Meier analysis of the overall survival or recurrence-free survival in HCC patients according to the concurrent expression of SMYD3 and ANKHD1
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[7]. However, the exact role of SMYD3 in promoting
tumor invasion and metastasis in HCC remains to be
elucidated. In this study, we demonstrated that SMYD3
was frequently upregulated in human HCC tissues and
was positively correlated with microvascular invasion,
malignant differentiation, and advanced TNM stage.
Multivariate analysis revealed that SMYD3 expression
level was an independent and significant risk factor for
survival and recurrence of HCC after curative resection.
Further studies showed that SMYD3 overexpression pro-
moted HCC cells migration and invasion via transacti-
vating Slug expression. This transactivation was through
increasing trimethylation of H3K4 and acetylation of
H3K9/14 in the SLUG gene promoter. Our data indicate
that SMYD3 acts as an epigenetic regulator in HCC,
resulting in HCC cells invasion and metastasis.
There are three histone lysine methylation states, in-
cluding monomethylation, dimethylation and trimethyla-
tion (me1, me2 and me3, respectively). Unlike histone
lysine acetylation, which decreases the positive charge
thus weakens electrostatic interactions between histones
and DNA, and reduces chromatin compaction, histone
lysine methylation cannot change the electronic charge
of the amino-acid side chain [24]. Therefore, histone ly-
sine methylation should function through effectors
which specifically recognize the methylated site and
regulate the transcriptional activity [25]. These “reader”
proteins generally contain methyl-lysine-binding motifs,
such as PHD, chromo, tudor, PWWP, WD40, BAH,
ADD, ankyrin repeat, MBT and zn-CW domains [26].
The methylated lysine-binding characteristic of anky-
rin repeat domain was first reported in 2008, as a func-
tional domain of G9a and GLP [18]. Robert and his
colleagues showed that G9a and GLP could not only
methylate H3K9, but also bind H3K9me1 and H3K9me2
through their ankyrin repeat domain, leading to tran-
scriptional repression [18]. In this study, we reported an-
other ankyrin repeat domain containing protein,
ANKHD1, could interact with H3K4me3 when cells
were overexpressing SMYD3. Moreover, our further ana-
lysis showed that ANKHD1 could bind to the specific
region at SLUG gene promoter in a SMYD3-dependent
manner and mediate the SMYD3-induced transactiva-
tion of SLUG gene promoter in HCC cell lines. In fact,
previous studies have shown ANKHD1 was an onco-
genic protein that could activate target genes transcrip-
tion [21, 27]. In addition, our data also showed that
ANKHD1 expression was associated with patient out-
comes in HCC and could mediate the pro-migratory and
pro-invasive effect of SMYD3, which was not reported
before. Therefore, our data reveal a new mechanism for
ANKHD1 in promoting tumor progression, serving as a
“reader” protein coordinating with SMYD3 to promote
target gene expression. However, further study is needed
to clarify the exact binding mechanism between
ANKHD1 and H3K4me3.
A major hallmark of aggressive HCC is its metastatic
capacity that can be characterized as vascular invasion
or intrahepatic metastasis [28]. Portal vein invasion is
the most common event among HCC patients with vas-
cular invasion [29]. Our results showed that SMYD3 ex-
pression was positively correlated with Slug expression,
but inversely correlated with E-cadherin expression in
not only HCC primary tissues, but also their vascular in-
vasion tissues (MVIs and mPVTTs). These findings
strongly suggest that SMYD3/Slug pathway plays an im-
portant role in promoting HCC metastasis and may be a
useful biomarker for HCC metastasis and poor
prognosis.
Conclusions
In summary, our study suggests that SMYD3-ANKHD1
axis is a new molecular mechanism for the regulation of
the target genes of SMYD3, such as Slug, which pro-
motes the invasion and metastasis of HCC. Targeting
SMYD3-ANKHD1 signaling may provide a potential
therapeutic opportunities against advanced HCC.
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